Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Washington Post Examines Health Toll Of Congo Conflict
The Washington Post examines the devastating toll the conflict in the Congo has had on the health of the country"s displaced civilians, as told through the death of a 36-year-old farmer, who succumbed to typhoid fever far away from the home he abandoned. The newspaper writes, "By some estimates, at least 5 million Congolese have died in more than a decade of conflict touched off by the 1994 genocide in neighboring Rwanda, which sent a flood of militiamen across the border into mineral-rich eastern Congo."
generic viagra online
7 Institutions To Receive $171 Million Over 5 Years To Help Researchers Turn Laboratory Discoveries Into Treatments For Patients
Clinical and Translational Science Awards (CTSAs) will be made to seven more academic health centers, bringing the consortium to 46 member institutions, the National Center for Research Res (NCRR), part of the National Institutes of Health, announced today. This national network of medical research institutions is working to accelerate the process that develops laboratory discoveries into treatments for patients, to engage communities in clinical research and to train a new generation of clinical and translational researchers.
News of the day
DaVita Study Demonstrates Clinical Application Of Sysmex Reticulocyte Hemoglobin Equivalent (RET-He) Parameter
Sysmex America, Inc. announced that a study titled "Day-to-Day, Week-to-Week, and Day-of-the-Week Variations in Tests of Anemia and Iron Status in Hemodialysis Patients" has identified Sysmex"s Reticulocyte Hemoglobin Equivalent (RET-He) parameter result as key input used by physicians to assist in Anemia treatment decisions in ESRD patients on hemodialysis. David Van Wyck, M.D., Vice President of Clinical Affairs at DaVita Inc., and Emeritus Professor of Medicine and Surgery at the University of Arizona College of Medicine, in Tucson et. al followed five hematologic parameters in 30 patients undergoing hemodialysis three times a week. The patients were followed for 12 consecutive treatment days. The parameters studied were Hb, Hct, reticulocyte Hb (RET He or CHr), TSAT and ferritin levels.
Cardiovascular

Osteoporosis Drug Heritage Continues Ahead Of 10th Anniversary

Data presented today at the 8th European Congress on Menopause (EMAS) demonstrated that the majority of osteoporosis patients treated with raloxifene stay on therapy for the first two years.(1) Prof. Dr. P. Hadji, University Hospital of Giessen and Marburg GmbH, Marburg, Germany, stated that "Of the 300 postmenopausal osteoporosis patients who received treatment with raloxifene, results show that at 12, 24 and 36 months 96.4 %, 80.5% and 62% respectively of patients remained on therapy." The data released today comes ahead of raloxifene"s 10th anniversary, a turning point that will not go unmarked. Coinciding with World Osteoporosis Day this October, plans are already underway to highlight the past and present success of the drug, as well as looking forward to a positive future. Reinhard Bauer, CEO of DAIICHI SANKYO EUROPE, says "DAIICHI SANKYO is delighted to mark the 10th anniversary of raloxifene later this year. The anniversary is intended to raise awareness of the disease and celebrate the role that raloxifene has played in transforming osteoporosis management over the years." The management of osteoporosis among postmenopausal women represents a major public health challenge because long-term treatment is required to prevent fractures and chronic disability.(2) Today"s results, together with the forthcoming anniversary of raloxifene, highlight how important it is for patients to continue to take their medication, in order to achieve treatment benefits and reduce the burden that osteoporosis places on individuals and the healthcare system.(3) "Patients often do not take their medication as prescribed and, as a result, current treatment with many osteoporosis therapies tends to be below standard," commented Prof. Dr. P. Hadji "However, raloxifene has a long and proven history of patient compliance. Years of research not only confirms that patients adhere to treatment regimens with the drug, but also demonstrates a safety profile that is as strong now, 10 years on, as it was when raloxifene first came to market." About raloxifene Raloxifene is a type of prescription medication called a Selective Estrogen Receptor Modulator (SERM). It is indicated for the treatment and prevention of osteoporosis in postmenopausal women. Raloxifene treats and prevents osteoporosis by reducing the risk of vertebral fracture. (4) Raloxifene has been taken by up to 26 million women worldwide, up to 7 million of them were treated in Europe.(5) About DAIICHI SANKYO DAIICHI SANKYO is a global pharmaceutical company that focuses on researching and marketing innovative medications. The company was created in 2005 through the merger of two traditional Japanese enterprises, Daiichi and Sankyo. With net sales of nearly 5.9 billion EUR in fiscal year 2008, DAIICHI SANKYO is one of the world"s 20 leading pharmaceutical companies. The company"s world headquarters is in Tokyo, and its European base is located in Munich. DAIICHI SANKYO has affiliates in 12 European countries and has been one of the strongest Japanese pharmaceutical companies located in Europe since it set up European production facilities and marketing offices in 1990. The company"s research activities focus on the areas of cardiovascular diseases, hematology, diabetes, anti-infectives and cancer. Its aim is to develop medications that are "best" in their class or to create new classes of pharmaceutical drugs. For more information, please visit: http://www.daiichi-sankyo.eu References 1. Hadji P, Wetzel K, Ziller V et al. (2009) Compliance during osteoporosis therapy with raloxifene. Poster presented at EMAS 2009 2. Turbi C, Herrero-Beaumont G, Acebes JC et al. (2004) Compliance and Satisfaction with Raloxifene Versus Alendronate for the Treatment of Postmenopausal Osteoporosis in Clinical Practice: An Open-Label, Prospective, Nonrandomized, Observational Study. Clin Therap 26; 245-256 3. Siris ES, Selby PL, Saag KG et al. (2009) Impact of Osteoporosis Treatment Adherence on Fracture Rates in North America and Europe. The American Journal of Medicine (2009) 122, S3-S13 4. Maricic M, Adachi JD, Sarkar S, Wu W, Wong M, Harper KD, (2002) Early effects of raloxifene on clinical vertebral fractures at 12 months in postmenopausal women with osteoporosis. Arch Intern Med.;162(10):1140-3. 5. Periodic safety Update Report, PSUR 16 Global (10-DEC-2007 TO 09-JUN 2008)/ Data on File DAIICHI SANKYO


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009